An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 1 Aug 2020 to 1 Sep 2022.
    • 18 Oct 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2022.
    • 07 Jul 2016 New data from this trial were presented at the XV International Symposium on Amyloidosis (ISA), according to an Ionis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top